| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.
AmeriVet Veterinary Partners is a company dedicated to supporting veterinary practices across the United States. Founded in 2016 and based in San Antonio, Texas, AmeriVet provides a range of business solutions that allow veterinary clinics to focus on animal care while benefiting from the companys resources and expertise. The services offered by AmeriVet include operational support, marketing strategies, professional training programs, human resources assistance, and financial management tools. These services are designed to enhance the efficiency and profitability of veterinary practices. AmeriVet operates on a partnership model, offering joint venture and full acquisition options that enable practice owners to maintain a stake in their business while accessing comprehensive support. With reported revenue of $205.5 million and significant funding, AmeriVet is recognized as a leading partner for veterinary clinics nationwide. The company has also been acknowledged as one of the top places to work in 2023, reflecting its commitment to a positive work environment for employees.